Is Trevi Therapeutics Inc (TRVI) overvalued? · $2.32B cap
Trevi Therapeutics Inc (TRVI) is a biotechnology company listed on NASDAQ.
This page asks whether Trevi Therapeutics Inc (TRVI) looks expensive on cached numbers — not a short thesis.
No cached income statement for TRVI, so there is no earnings base to call rich or cheap.
TRVI currently screens at market cap $2.32B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TRVI 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TRVI stock page for the full model, not this heading.
Not investment advice.